Lv71
4938 积分 2022-08-01 加入
Anti-drug Antibody Validation Testing and Reporting Harmonization Addendum
2天前
已完结
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial
6天前
已完结
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
7天前
已完结
Uncommon EGFR mutations in advanced non-small cell lung cancer
7天前
已完结
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
9天前
已完结
Compound EGFR Mutations Are Predominantly P-Loop and Alpha-C Helix Compressing Mutations With Increased Responsiveness to Second- Versus Third-Generation Tyrosine Kinase Inhibitors
14天前
已关闭
Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): ‘Where the streets have no name’
14天前
已完结
Survival analysis and prognostic factors in advanced NSCLC harboring EGFR PACC mutations: A multicenter retrospective study
14天前
已完结
Targeting RET mutation in medullary thyroid cancer
15天前
已完结
Targeting RET mutation in medullary thyroid cancer
15天前
已关闭
皖公网安备34019202002308
